(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of Principal Executive Offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Executive | Title | 2022 Base Salary | ||||||
Jay Venkatesan | President & Chief Executive Officer | $608,000.00 | ||||||
John Neylan | Executive Vice President, Chief Medical Officer and Head of Research | $485,100.00 | ||||||
Jennifer J. Rhodes | Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Secretary | $440,840.00 |
Executive | Title | Shares Subject to Stock Option Granted | ||||||
Jay Venkatesan | President & Chief Executive Officer | 600,000 | ||||||
John Neylan | Executive Vice President, Chief Medical Officer and Head of Research | 175,000 | ||||||
Jennifer J. Rhodes | Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Secretary | 175,000 | ||||||
Greg Curhan | Chief Financial Officer* | 100,000 |
Executive | Title | Shares Subject to Stock Option Granted | ||||||
Jay Venkatesan | President & Chief Executive Officer | 160,000 | ||||||
John Neylan | Executive Vice President, Chief Medical Officer and Head of Research | 100,000 | ||||||
Jennifer J. Rhodes | Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Secretary | 100,000 |
ANGION BIOMEDICA CORP. | |||||||||||||||||
By: | /s/ Jennifer J. Rhodes | ||||||||||||||||
Date: March 4, 2022 | Jennifer J. Rhodes Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Secretary |
Document and Entity Information Document |
Mar. 03, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Mar. 02, 2022 |
Entity Registrant Name | ANGION BIOMEDICA CORP. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-39990 |
Entity Tax Identification Number | 11-3430072 |
Entity Address, Address Line One | 51 Charles Lindbergh Boulevard |
Entity Address, City or Town | Uniondale |
Entity Address, State or Province | NY |
Entity Address, Postal Zip Code | 11553 |
City Area Code | 415 |
Local Phone Number | 655-4899 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | ANGN |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Entity Central Index Key | 0001601485 |
Amendment Flag | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G
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
&UL4$L! A0#% @ .()D5 B')CKG!@ 2#, !4 ( ! M524 &%N9VXM,C R,C S,#)?<')E+GAM;%!+!08 ! $ 0! !O+ " ! end